The publisher regrets that the term “CaLIPSO” was incorrectly identified as an acronym. The sentence in question has been corrected to “In the phase 2b CaLIPSO trial of patients receiving maintenance hemodialysis, SNF472 significantly reduced the progression of CACvs compared with placebo in an mITT population, and the effect was confirmed in a PP population.4”
The publisher would like to apologise for any inconvenience caused.
DOI of original article: https://doi.org/10.1016/j.ekir.2020.09.032
Correspondence: Paolo Raggi, Division of Cardiology, University of Alberta, 5A9-014, 11220 83rd Avenue NW, Edmonton, Alberta T6G 2B7, Canada. E-mail: raggip@gmail.com